News

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion - MSN
Novartis agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company ...
Business Wire4mon
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire
Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI ...
Seeking Alpha2mon
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with ... - Seeking Alpha
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...
Wall Street Journal4mon
Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion - WSJ - The Wall Street Journal
Novartis NOVN-0.63 % decrease; red down pointing triangle agreed to acquire Blackstone Life Sciences’ Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline.
U.S. News & World Report4mon
Novartis Buys Blackstone's Anthos for up to $3.1 Billion - U.S. News
Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the ...
PE Hub4mon
Blackstone sells Anthos to Novartis for up to $3.1bn
Anthos was founded by Blackstone Life Sciences and Novartis in 2019. Sophie Rose - 11 February 2025. Share A-A + 100%. Anthos is a transformative, clinical-stage biopharmaceutical company; ...
HealthLeaders Media4mon
Novartis to buy Anthos Therapeutics from Blackstone for up to $3.1B
Novartis agreed to acquire Blackstone Life Sciences' Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular-drug pipeline. The deal means the Swiss pharmaceutical company retakes ...
Nasdaq4mon
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Nasdaq
Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases ...
Morningstar2mon
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with ... - Morningstar
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront.
Reuters4mon
Novartis buys Blackstone's Anthos for up to $3.1 billion
Novartis buys Blackstone's Anthos for up to $3.1 billion. By Ludwig Burger and Ariane Luthi. February 11, 2025 3:21 PM UTC Updated February 11, 2025 The company's logo is seen at ...
AFP4mon
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...